EE200300577A - Ravimikombinatsioon, mis sisaldab kas (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhapet või 3-{4-[2-(4-tert-butoksükarbonüülaminofenüül)etoksü]fenüül}-(S)-2-etoksüpropaanhapet ja insuliini - Google Patents

Ravimikombinatsioon, mis sisaldab kas (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhapet või 3-{4-[2-(4-tert-butoksükarbonüülaminofenüül)etoksü]fenüül}-(S)-2-etoksüpropaanhapet ja insuliini

Info

Publication number
EE200300577A
EE200300577A EEP200300577A EEP200300577A EE200300577A EE 200300577 A EE200300577 A EE 200300577A EE P200300577 A EEP200300577 A EE P200300577A EE P200300577 A EEP200300577 A EE P200300577A EE 200300577 A EE200300577 A EE 200300577A
Authority
EE
Estonia
Prior art keywords
ethoxy
phenyl
methanesulfonyloxyphenyl
butoxycarbonylaminophenyl
insulin
Prior art date
Application number
EEP200300577A
Other languages
English (en)
Inventor
Hman Peter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200300577A publication Critical patent/EE200300577A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200300577A 2001-06-01 2002-05-30 Ravimikombinatsioon, mis sisaldab kas (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhapet või 3-{4-[2-(4-tert-butoksükarbonüülaminofenüül)etoksü]fenüül}-(S)-2-etoksüpropaanhapet ja insuliini EE200300577A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101981A SE0101981D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination
PCT/SE2002/001037 WO2002096453A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin

Publications (1)

Publication Number Publication Date
EE200300577A true EE200300577A (et) 2004-02-16

Family

ID=20284363

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300577A EE200300577A (et) 2001-06-01 2002-05-30 Ravimikombinatsioon, mis sisaldab kas (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhapet või 3-{4-[2-(4-tert-butoksükarbonüülaminofenüül)etoksü]fenüül}-(S)-2-etoksüpropaanhapet ja insuliini

Country Status (22)

Country Link
US (1) US20040147600A1 (et)
EP (1) EP1401485A1 (et)
JP (1) JP2004532873A (et)
KR (1) KR20040072027A (et)
CN (1) CN1535155A (et)
BR (1) BR0210129A (et)
CA (1) CA2448637A1 (et)
CO (1) CO5540383A2 (et)
CZ (1) CZ20033233A3 (et)
EE (1) EE200300577A (et)
HU (1) HUP0400964A3 (et)
IL (1) IL159034A0 (et)
IS (1) IS7056A (et)
MX (1) MXPA03011012A (et)
NO (1) NO20035236D0 (et)
NZ (1) NZ529812A (et)
PL (1) PL367704A1 (et)
RU (1) RU2003136156A (et)
SE (1) SE0101981D0 (et)
SK (1) SK14712003A3 (et)
WO (1) WO2002096453A1 (et)
ZA (1) ZA200309261B (et)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60308390T2 (de) * 2003-11-28 2007-09-06 Merck Santé Behandlung von Hyperurikämie
PE20061041A1 (es) * 2005-01-28 2006-10-12 Lilly Co Eli Formulaciones y regimen de dosificacion para moduladores alfa de ppar
WO2009142713A1 (en) * 2008-05-19 2009-11-26 Nestec S.A. Methods for reducing lipid absorption by an animal

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
PT1145717E (pt) * 2000-04-13 2004-08-31 Pfizer Prod Inc Efeito sinergistico de gliburide e milrinona

Also Published As

Publication number Publication date
CZ20033233A3 (cs) 2004-12-15
JP2004532873A (ja) 2004-10-28
WO2002096453A1 (en) 2002-12-05
NO20035236D0 (no) 2003-11-25
HUP0400964A2 (hu) 2004-08-30
CN1535155A (zh) 2004-10-06
SK14712003A3 (sk) 2004-08-03
IS7056A (is) 2003-11-28
ZA200309261B (en) 2005-02-28
MXPA03011012A (es) 2004-02-27
IL159034A0 (en) 2004-05-12
HUP0400964A3 (en) 2007-11-28
NZ529812A (en) 2006-03-31
BR0210129A (pt) 2004-06-08
CO5540383A2 (es) 2005-07-29
PL367704A1 (en) 2005-03-07
SE0101981D0 (sv) 2001-06-01
RU2003136156A (ru) 2005-05-20
KR20040072027A (ko) 2004-08-16
EP1401485A1 (en) 2004-03-31
US20040147600A1 (en) 2004-07-29
CA2448637A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
BR9910913A (pt) Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, e, processo para a profilaxia e/ou tratamento de condições clìnicas associadas com resistência a insulina
HRP20010580B1 (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU3957800A (en) Crystalline r- guanidines, arginine or (l) -arginine (2(s)) -2- ethoxy -3-(4- (2-(10(h) -phenoxazin -10-yl)ethoxy}phenyl)propanoate
NZ513061A (en) Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the treatment of diabetic neuropathy
BR0312103A (pt) Combinações de substâncias ativas fungicidas
SI1667964T1 (sl) 4-((fenoksialkil)tio)-fenoksiocetne kisline in analogi
EA200401136A1 (ru) Предназначенная для перорального применения лекарственная форма для этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его солей
DK1237855T3 (da) Krystallinsk form af (S)-2-ethoxy-3-[4-(2-(4-methansulfonyloxyphenyl)ethoxy)phenyl]propansyre
NO20003069L (no) 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl]tiazolidin- 2,4-dion-maleinsyre-salt-hydrat som farmasøytikum
PL355372A1 (en) Comminuted form of (s)-2-ethoxy -3-[4-(2- {4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
EE200300577A (et) Ravimikombinatsioon, mis sisaldab kas (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhapet või 3-{4-[2-(4-tert-butoksükarbonüülaminofenüül)etoksü]fenüül}-(S)-2-etoksüpropaanhapet ja insuliini
EE200300583A (et) Ravimikombinatsioon, mis sisaldab kas (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhapet või 3-{4-[2-(4-tert-butoksükarbonüülaminofenüül)etoksü]fenüül}-(S)-2-etoksüpropaanhapet ja sulfonüüluureat
EE200300584A (et) Ravimikombinatsioon, mis sisaldab kas (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhapet või 3-{4-[2-(4-tert-butoksükarbonüülaminofenüül)etoksü]fenüül}-(S)-2-etoksüpropaanhapet ja biguaniidravimit
IS8224A (is) Amínsölt (-)-2-{[2-(4-hýdroxýfenýl)etýl]-þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}etýl)fenýl]própansýru og notkun þeirra í læknisfræði
NO20000665D0 (no) 2-{3-[4-(2-t-Butyl-6-trifluormetyl-4-pyrimidinyl)-1- piperazinyl]propyltio}-4-pyrimidinol-fumarat
HK1062527A (en) A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a sulonylurea
HK1087396A (en) Potassium or sodium salt of (-)-2- {'2-(4-hydroxyphenyl)ethyl]-thio -3-'4-(2- {4-'(methylsulfonyl)oxy ]phenoxy }phenyl]propanoic acid and their use in medicine.
AU2001290743A1 (en) Solid salt forms of n-(2-(4-(2-(1-methylethoxy)phenyl)-1-piperazinyl)ethyl)-2-oxo-1-piperidineacetamide
HK1087395A (en) Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio} -3-{4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid
TH95774A (th) สูตรผสมทางเภสัชกรรมชนิดน้ำของ 4-[((4-คาร์บอกซีบิวทิล)-{2-[(4-เฟนเนทธิลเบนซิล)ออกซี]เฟนเนทธิล}อะมิโน)เมทธิล]เบนโซอิคแอซิด
FI980508A0 (fi) 2-(3,5-difluorfenyl)-3-(4-(metylsulfonyl)fenyl)-2-cyklopenten-1-on anvaendbar som COX-2 inhibitor
SE9904416D0 (sv) Crystalline form